Metformina + Pioglitazona Pentafarma

Metformin Hydrochloride, the active ingredient in Metformina + Pioglitona Pentafarma, is a biguanide presented as an oral tablet for oral use. It is combined with pioglitazone, a thiazolidinedione, to treat type 2 diabetes mellitus in adult patients who require additional glycemic control.

GNH USA supplies Metformina + Pioglitona Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Pioglitona Pentafarma is used in the management of type 2 diabetes mellitus and related hyperglycaemic conditions. - Type 2 diabetes mellitus: improves overall glycaemic control when monotherapy is insufficient. - Elevated fasting plasma glucose: lowers fasting glucose levels. - High HbA1c: reduces HbA1c percentages toward target values. - Insulin resistance: enhances peripheral insulin sensitivity. - Hyperglycaemia after meals: attenuates post‑prandial glucose excursions.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhoea: frequent loose stools, especially at treatment initiation. - Weight gain: modest increase due to fluid retention or adipose tissue changes. - Edema: peripheral swelling, often in the ankles. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Heart failure exacerbation: fluid overload leading to dyspnoea. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Bone fracture: increased risk of osteoporotic fractures. - Bladder cancer: potential association with long‑term pioglitazone use.

Patients should be evaluated for specific risk factors before initiating therapy. - Renal function: assess creatinine clearance and adjust if impaired. - Hepatic function: monitor liver enzymes prior to and during treatment. - Cardiac status: evaluate for existing heart failure before use. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Concomitant medications: review for drugs that may affect glucose or renal function. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformina + Pioglitona Pentafarma can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Cimetidine: may raise metformin plasma concentrations. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): elevate pioglitazone levels.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate fluid retention and edema. - ACE inhibitors or ARBs: monitor renal function and potassium. - Contrast media: temporary suspension of metformin recommended to avoid renal complications.